EP1904469B1 - New pyrocatechin derivatives - Google Patents
New pyrocatechin derivatives Download PDFInfo
- Publication number
- EP1904469B1 EP1904469B1 EP06762514A EP06762514A EP1904469B1 EP 1904469 B1 EP1904469 B1 EP 1904469B1 EP 06762514 A EP06762514 A EP 06762514A EP 06762514 A EP06762514 A EP 06762514A EP 1904469 B1 EP1904469 B1 EP 1904469B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- alkoxy
- group
- alkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 0 *CC(C1=CCC(*)C(OC(Oc2cc(*(C*)=O)ccc2*)=O)=C1)=O Chemical compound *CC(C1=CCC(*)C(OC(Oc2cc(*(C*)=O)ccc2*)=O)=C1)=O 0.000 description 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
- C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/228—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing six-membered aromatic rings, e.g. phenylacetaldehyde
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C68/00—Preparation of esters of carbonic or haloformic acids
- C07C68/06—Preparation of esters of carbonic or haloformic acids from organic carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
Definitions
- the invention relates to new compounds of formula I wherein R is a group of formulae la, Ib, Ic or Id R 1 is 4-halogenbut-2-enyl , R 2 is C 1 -C 7 - alkyl or cycloalkyl, R 3 is C 1 -C 7 - alkoxy, R 4 is C 1 -C 7 - alkoxy - C 1 -C 7 - alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxyl C 1 -C 7 - alkoxy or a group of formula Ie R 5 is reactive, esterified hydroxyl as defined in claim 1, R 6 is azido and R 7 is C 1 -C 7 - alkyl, C 1 -C 7 - alkenyl, cycloalkyl or aryl C 1 -C 7 - alkyl, and their salts, a process for their preparation and their use as intermediates in the production of active ingredients for medicaments.
- Halobut-2-enyl is, for example, 4-bromobut-2-enyl or 4-chlorobut-2-enyl, especially 4-bromobut-2-enyl.
- Cycloalkyl has, for example, 3 to 8 , preferably 3 ring members, and signifies primarily cyclopropyl, or also cyclobutyl, cyclopentyl or cyclohexyl.
- Reactive esterified hydroxy is halogen or C 1 -C 7 - alkanesulfonyloxy, halogen C 1 -C 7 - alkanesulfonyl, or benzenesulfonyloxy or naphthalenesulfonyloxy either unsubstituted or substituted by C 1 -C 7 - alkyl, halogen and/or nitro.
- C 1 -C 7 - radicals and compounds is understood, for example, those radicals and compounds having up to and including 7, preferably up to and including 4 carbon atoms (C-atoms).
- Halogen is, for example, halogen with an atomic number from 19 to 35, such as chlorine or in particular bromine.
- Halogen C 10 -C 7 - alkanesulfonyloxy is, for example, polyhalogen-C 1 -C 4 -alkanesulfonyloxy, such as trifluoromethanesulfonyloxy.
- C 1 -C 7 - alkanesulfonyloxy is, for example C 1 -C 4 -alkanesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, propanesulfonyloxy or butanesulfonyloxy.
- C 1 -C 7 - alkenyl may be straight-chained or branched and is for example a corresponding C 2 -C 4 -alkenyl, such as allyl.
- C 1 -C 7 - alkenesulfonyloxy is, for example C 2 -C 4 -alkenesulfonyloxy, such as ethenesulfonyloxy.
- C 1 -C 7 - alkyl may be straight-chained or branched and is, for example, corresponding C 1 -C 7 -alkyl, especially C 1 -C 4 -alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl or a pentyl, hexyl or heptyl group.
- Lower alkyl R 2 or R 5 is, for example, methyl or in particular branched C 3 -C 7 -alkyl, such as propyl.
- C 1 -C 7 - alkoxy is, for example, C 1 -C 7 -alkoxy, preferably C 1 -C 4 -alkoxy, such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, secondary butyloxy, tertiary butyloxy, pentyloxy or a hexyloxy or heptyloxy group.
- Hydroxy C 1 -C 7 - alkoxy is, for example, hydroxy-C 2 -C 4 -alkoxy, such as 2-hydroxyethoxy, 3-hydroxypropyloxy or 4-hydroxybutyloxy, especially 3-hydroxypropyloxy or 4-hydroxybutyloxy.
- C 1 -C 7 - alkoxy is, for example, C 1 -C 4 -alkoxy-C 2 -C 4 -alkoxy, such as 2-methoxy-, 2-ethoxy- or 2-propyloxyethoxy, 3-methoxy- or 3-ethoxypropyloxy or 4-methoxybutyloxy, especially 3-methoxypropyloxy or 4-methoxybutyloxy.
- Phenyl C 1 -C 7 - alkyl is, for example, phenyl-C 1 -C 4 -alkyl, preferably 1-phenyl-C 1 -C 4 -alkyl, such as benzyl or 1-phenylethyl.
- Salts are especially phenolate salts of compounds of formula I, wherein R 4 is hydroxy with appropriate bases, such as metal salts derived from metals of group Ia, Ib, IIa and IIb of the periodic table of elements, e.g. alkali metal salts, especially lithium, sodium or potassium salts, alkaline earth metal salts, for example magnesium or calcium salts, also zinc salts.
- appropriate bases such as metal salts derived from metals of group Ia, Ib, IIa and IIb of the periodic table of elements, e.g. alkali metal salts, especially lithium, sodium or potassium salts, alkaline earth metal salts, for example magnesium or calcium salts, also zinc salts.
- the invention was based on the problem of developing an improved method of obtaining compounds of formula II wherein R 2 , R 3 and R 7 have the indicated significances, and R 4 signifies C 1 -C 7 - alkoxy lower alkoxy, which are valuable intermediates for the production of active ingredients for medicaments.
- R 2 , R 3 , R 4 and R 7 have the indicated significances
- R 4 signifies C 1 -C 7 -alkoxy lower alkoxy
- R 8 signifies C 1 -C 7 -alkyl, cycloalkyl, optionally aliphatically esterified or etherified hydroxy C 1 -C 7 -alkyl, optionally N- C 1 -C 7 - alkanoylated, N-mono- or N,N-di C 1 -C 7 - alkylated amino C 1 -C 7 -alkyl, or amino C 1 -C 7 -alkyl N,N-disubstituted by C 1 -C 7 -alkylene, hydroxy-, C 1 -C 7 -alkoxy- or C 1 -C 7 -alkanoyloxy C 1 -C 7 -alkylene
- the intermediates of formula II are at present prepared in a four-step synthesis from 2- C 1 -C 7 - alkoxyphenols on the one hand and phenyl alaninol on the other hand, in accordance with the following scheme.
- Verther et al. Journal of Chemical Engineering Data, American Chemical Society, US, Vol. 9, No. 3, 1964, 403-404 , discloses the synthesis of 3-hydroxy-4-methoxy butyrophenone.
- WO 02/02508 and WO 02/08172 disclose pharmaceutically active compounds.
- the solution to the problem according to the invention is based on the consideration that instead of halogenated, it is more advantageous to use acylated 2- C 1 -C 7 - alkoxyphenols, which already contain part of the side chain, and is based on the surprising discovery that the acylation of 2,2'-di C 1 -C 7 - alkoxy diphenylcarbonates takes place with high selectivity in p-position to the C 1 -C 7 - alkoxy groups.
- the process according to the invention uses methods which can be carried out more easily on a technical scale and are less problematic from an ecological and safety point of view than the known process. Accordingly the present invention provides the subject matter of claim 1 to 6.
- the solution, according to the invention, to the problem of producing the intermediates II is clarified by the following reaction scheme.
- steps E and F can also be exchanged by reacting the 1,4-dihalogen-but-2-ene in accordance with the reaction scheme first of all with the chiral amide and then with the chiral ketimine which is obtainable according to steps D+E.
- R' 4 signifies hydroxy C 1 -C 7 - alkoxy
- R" 4 signifies C 1 -C 7 -alkoxy C 1 -C 7 - alkoxy
- X 1 signifies the imino group derived from a chiral primary amine which is customary for the purpose of stereoselective synthesis, such as (S)-1-phenylethylamine or (S)-2-amino-1-methoxy-3-phenylpropane
- X 2 signifies a chiral amino, amido or urethane group which is customary for the purpose of stereoselective synthesis, or a chiral alcohol group.
- Compounds containing groups of this kind are, for example, pseudoephedrine, 4(S)-benzyl-2-oxo-oxazolidine, camphor sultam, borneol, intermediately-protected (S,S)- or (R,R)-2-aminophenylpropanediol, menthol, 8-phenylmenthol, pantolactone and the like.
- the invention also relates to steps A, B, C, D+E, F+G or F'+F'+G and H for their production, and the whole process, comprising these steps, for producing compounds of formula I, wherein R is a group of formulae Ic and Id, R 2 is C 1 -C 7 - alkyl or cycloalkyl, R 3 is C 1 -C 7 - alkoxy, R 4 is C 1 -C 7 - alkoxy C 1 -C 7 - alkoxy, R 5 is reactive esterified hydroxyl as defined in claim 1, especially halogen, R 6 is azido and R 7 is C 1 -C 7 - alkyl, C 1 -C 7 - alkenyl, cycloalkyl or aryl C 1 -C 7 - alkyl.
- the invention relates primarily to compounds of formula I, wherein R illustrates a group of formulae la, Ib, Ic or Id, R 1 is 4-halogenbut-2-enyl , R 2 is C 1 -C 7 - alkyl or 3- to 8-membered cycloalkyl, R 3 is C 1 -C 7 - alkoxy, R 4 illustrates C 1 -C 7 - alkoxy C 1 -C 7 - alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy C 1 -C 7 - alkoxy or a group of formula Ie.
- R 5 is halogen or sulfonyloxy, such as C 1 -C 7 - alkane sulfonyloxy, halogen C 1 -C 7 - alkane sulfonyl, C 1 -C 7 - alkane sulfonyloxy; or benzene sulfonyloxy or naphthalene sulfonyloxy which is unsubstituted or substituted by C 1 -C 7 - alkyl, halogen and/or nitro.
- sulfonyloxy such as C 1 -C 7 - alkane sulfonyloxy, halogen C 1 -C 7 - alkane sulfonyl, C 1 -C 7 - alkane sulfonyloxy; or benzene sulfonyloxy or naphthalene sulfonyloxy which is unsubstituted or substitute
- R 6 is azido and R 7 is C 1 -C 7 - alkyl, C 1 -C 7 - alkenyl, 3- to 8-membered cycloalkyl, or phenyl C 1 -C 7 - alkyl which is unsubstituted or substituted in the phenyl moiety by C 1 -C 7 - alkyl, C 1 -C 7 - alkoxy, halogen and/or nitro, and their salts, a process for their preparation and their use as intermediates in the production of active ingredients for medicaments.
- the invention preferably relates to compounds of formula I, wherein R illustrates a group of formulae Ia, Ib, Ic or Id, R 1 is 4-halogenbut-2-enyl , R 2 is branched C 3 -C 7 -alkyl, such as propyl, R 3 is C 1 -C 4 -alkoxy, such as methoxy, R 4 is C 1 -C 4 -alkoxy-C 2 -C 4 -alkoxy, such as 3-methoxypropyloxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy-C 2 -C 4 -alkoxy, such as 3-hydroxypropyloxy, or a group of formula Ie, R 5 is halogen of atomic numbers up to and including 35, such as bromine, R 6 is azido or amino and R 7 is branched C 3 -C 7 -alkyl, such as propyl, and their salts, a process for their preparation and their use as intermediates
- the invention relates specifically to the compounds of formula I and their salts named in the examples, processes for their preparation, and their use as intermediates for producing active ingredients for medicaments.
- Salts of compounds of formula I and II which are obtainable by the process, can be converted in known manner into the free compounds.
- salts of compounds of formula II can be converted by treatment with a base, such as an alkali metal hydroxide, a metal carbonate or hydrogen carbonate, or ammonia, or with another salt-forming base mentioned initially, or with an acid, such as a mineral acid, e.g. hydrochloric acid, or with another salt-forming acid mentioned initially.
- a base such as an alkali metal hydroxide, a metal carbonate or hydrogen carbonate, or ammonia
- an acid such as a mineral acid, e.g. hydrochloric acid, or with another salt-forming acid mentioned initially.
- Example 7 trans -1-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl1-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-2(S)-7(S)-diisopropyl-oct-4-en-1,8-dione
- the solution obtained is added dropwise at 0°C to a solution of 8 g of trans-1-bromo-6-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-5-(S)-isopropyl-hex-2-en-6-one in 10 ml of tolulene. After stirring, the mixture is acidified with diluted hydrochloric acid, separated, and the organic solution concentrated. The crude product is purified by chromatography on a column of silica gel (eluant: hexane/ethyl acetate 85:15).
Abstract
Description
- The invention relates to new compounds of formula I
R is a group of formulae la, Ib, Ic or Id
R2 is C1-C7- alkyl or cycloalkyl,
R3 is C1-C7- alkoxy,
R4 is C1-C7- alkoxy - C1-C7- alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxyl C1-C7- alkoxy or a group of formula Ie
R6 is azido and
R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl,
and their salts, a process for their preparation and their use as intermediates in the production of active ingredients for medicaments. - Halobut-2-enyl is, for example, 4-bromobut-2-enyl or 4-chlorobut-2-enyl, especially 4-bromobut-2-enyl.
- Cycloalkyl has, for example, 3 to 8 , preferably 3 ring members, and signifies primarily cyclopropyl, or also cyclobutyl, cyclopentyl or cyclohexyl.
- Reactive esterified hydroxy is halogen or C1-C7- alkanesulfonyloxy, halogen C1-C7- alkanesulfonyl, or benzenesulfonyloxy or naphthalenesulfonyloxy either unsubstituted or substituted by C1-C7- alkyl, halogen and/or nitro.
- Hereinbefore and hereinafter, by C1-C7- radicals and compounds is understood, for example, those radicals and compounds having up to and including 7, preferably up to and including 4 carbon atoms (C-atoms).
- Halogen is, for example, halogen with an atomic number from 19 to 35, such as chlorine or in particular bromine.
- Halogen C10-C7- alkanesulfonyloxy is, for example, polyhalogen-C1-C4-alkanesulfonyloxy, such as trifluoromethanesulfonyloxy.
- C1-C7- alkanesulfonyloxy is, for example C1-C4-alkanesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, propanesulfonyloxy or butanesulfonyloxy.
- C1-C7- alkenyl may be straight-chained or branched and is for example a corresponding C2-C4-alkenyl, such as allyl.
- C1-C7- alkenesulfonyloxy is, for example C2-C4-alkenesulfonyloxy, such as ethenesulfonyloxy.
- C1-C7- alkyl may be straight-chained or branched and is, for example, corresponding C1-C7-alkyl, especially C1-C4-alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl or a pentyl, hexyl or heptyl group. Lower alkyl R2 or R5 is, for example, methyl or in particular branched C3-C7-alkyl, such as propyl.
- C1-C7- alkoxy is, for example, C1-C7-alkoxy, preferably C1-C4-alkoxy, such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, secondary butyloxy, tertiary butyloxy, pentyloxy or a hexyloxy or heptyloxy group.
- Hydroxy C1-C7- alkoxy is, for example, hydroxy-C2-C4-alkoxy, such as 2-hydroxyethoxy, 3-hydroxypropyloxy or 4-hydroxybutyloxy, especially 3-hydroxypropyloxy or 4-hydroxybutyloxy.
- C1-C7- alkoxy C1-C7- alkoxy is, for example, C1-C4-alkoxy-C2-C4-alkoxy, such as 2-methoxy-, 2-ethoxy- or 2-propyloxyethoxy, 3-methoxy- or 3-ethoxypropyloxy or 4-methoxybutyloxy, especially 3-methoxypropyloxy or 4-methoxybutyloxy.
- Phenyl C1-C7- alkyl is, for example, phenyl-C1-C4-alkyl, preferably 1-phenyl-C1-C4-alkyl, such as benzyl or 1-phenylethyl.
- Salts are especially phenolate salts of compounds of formula I, wherein R4 is hydroxy with appropriate bases, such as metal salts derived from metals of group Ia, Ib, IIa and IIb of the periodic table of elements, e.g. alkali metal salts, especially lithium, sodium or potassium salts, alkaline earth metal salts, for example magnesium or calcium salts, also zinc salts.
- The invention was based on the problem of developing an improved method of obtaining compounds of formula II
EP-678503 -
- On a technical scale, the production of these starting materials and their further processing to the intermediates II is extremely complex, technical and, from a safety point of view, difficult to control, and expensive. There was therefore an urgent need for an improved and technically practicable alternative process for the production of compounds of formula II. Berlin et al., Tetrahedron, Vol. 20, No. 11, 1964, 2709-2716, discloses synthetic procedures for the condensation of arenediols with phenyl phosphonic dichloride.
- Arnoldi et al., Journal of Agricultural and Food Chemistry, Vol. 34, No. 2, 1986, 339-344, discloses various 2-phenyl benzodioxanes.
- Verther et al., Journal of Chemical Engineering Data, American Chemical Society, US, Vol. 9, No. 3, 1964, 403-404, discloses the synthesis of 3-hydroxy-4-methoxy butyrophenone.
- Forrest et al. Canadian Journal of Chemistry, Vol. 52, No. 22, 1974, 3784-3786, discloses studies on the cleavage of the methylene dioxy ring of the Grignard reaction of 3,4-methylene dioxybenzonitrile.
-
WO 02/02508 WO 02/08172 - The solution to the problem according to the invention is based on the consideration that instead of halogenated, it is more advantageous to use acylated 2- C1-C7- alkoxyphenols, which already contain part of the side chain, and is based on the surprising discovery that the acylation of 2,2'-di C1-C7- alkoxy diphenylcarbonates takes place with high selectivity in p-position to the C1-C7- alkoxy groups. The process according to the invention uses methods which can be carried out more easily on a technical scale and are less problematic from an ecological and safety point of view than the known process.
Accordingly the present invention provides the subject matter of claim 1 to 6.
The solution, according to the invention, to the problem of producing the intermediates II is clarified by the following reaction scheme. -
- In the depicted reaction schemes, R'4 signifies hydroxy C1-C7- alkoxy, R"4 signifies C1-C7-alkoxy C1-C7- alkoxy, X1 signifies the imino group derived from a chiral primary amine which is customary for the purpose of stereoselective synthesis, such as (S)-1-phenylethylamine or (S)-2-amino-1-methoxy-3-phenylpropane, and X2 signifies a chiral amino, amido or urethane group which is customary for the purpose of stereoselective synthesis, or a chiral alcohol group. Compounds containing groups of this kind are, for example, pseudoephedrine, 4(S)-benzyl-2-oxo-oxazolidine, camphor sultam, borneol, intermediately-protected (S,S)- or (R,R)-2-aminophenylpropanediol, menthol, 8-phenylmenthol, pantolactone and the like.
- In addition to the compounds of formula I prepared according to the invention, the invention also relates to steps A, B, C, D+E, F+G or F'+F'+G and H for their production, and the whole process, comprising these steps, for producing compounds of formula I, wherein R is a group of formulae Ic and Id, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy, R5 is reactive esterified hydroxyl as defined in claim 1, especially halogen, R6 is azido and R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl.
- The use of compounds of formula I for the production of intermediates of formula II, in order to produce active ingredients for medicaments, of formula III, described in
EP-678503 - The invention relates primarily to compounds of formula I, wherein
R illustrates a group of formulae la, Ib, Ic or Id,
R1 is 4-halogenbut-2-enyl ,
R2 is C1-C7- alkyl or 3- to 8-membered cycloalkyl,
R3 is C1-C7- alkoxy,
R4 illustrates C1-C7- alkoxy C1-C7- alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy C1-C7- alkoxy or a group of formula Ie.
R5 is halogen or sulfonyloxy, such as C1-C7- alkane sulfonyloxy, halogen C1-C7- alkane sulfonyl, C1-C7- alkane sulfonyloxy; or benzene sulfonyloxy or naphthalene sulfonyloxy which is unsubstituted or substituted by C1-C7- alkyl, halogen and/or nitro.
R6 is azido and
R7 is C1-C7- alkyl, C1-C7- alkenyl, 3- to 8-membered cycloalkyl, or phenyl C1-C7- alkyl which is unsubstituted or substituted in the phenyl moiety by C1-C7- alkyl, C1-C7- alkoxy, halogen and/or nitro,
and their salts, a process for their preparation and their use as intermediates in the production of active ingredients for medicaments. - The invention preferably relates to compounds of formula I, wherein
R illustrates a group of formulae Ia, Ib, Ic or Id,
R1 is 4-halogenbut-2-enyl ,
R2 is branched C3-C7-alkyl, such as propyl,
R3 is C1-C4-alkoxy, such as methoxy,
R4 is C1-C4-alkoxy-C2-C4-alkoxy, such as 3-methoxypropyloxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy-C2-C4-alkoxy, such as 3-hydroxypropyloxy, or a group of formula Ie,
R5 is halogen of atomic numbers up to and including 35, such as bromine,
R6 is azido or amino and
R7 is branched C3-C7-alkyl, such as propyl,
and their salts, a process for their preparation and their use as intermediates in the production of active ingredients for medicaments. - The invention relates specifically to the compounds of formula I and their salts named in the examples, processes for their preparation, and their use as intermediates for producing active ingredients for medicaments.
- The process according to the invention for the preparation of the compounds of formula I is characterised in that
- a) in order to produce compounds of formula I, wherein R is a group of formula Ia, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is a group of formula Ie,
a compound of formula IV - b) in order to produce a compound of formula I, wherein R is a group of formula la, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is hydroxy, a compound of formula VI,
- c) in order to produce a compound of formula I, wherein R is a group of formula la, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is hydroxy C1-C7- alkoxy R'4, in a compound of formula VII,
- d) in order to produce a compound of formula I, wherein R is a group of formula la, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is C1-C7- alkoxy C1-C7- alkoxy R"4, in a compound of formula VIII,
- e) in order to produce compounds of formula I, wherein R is a group of formula Ib, R1 is 4-halogen-but-2-enyl, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is C1-C7-alkoxy C1-C7- alkoxy R"4, a compound of formula IX
- f) in order to produce compounds of formula I, wherein R is a group of formula Ic, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy R"4, R5 is reactive esterified hydroxyl as defined in claim 1 and R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl,
a compound of formula X, - g) in order to produce compounds of formula I, wherein R is a group of formula Id, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy R"4, R6 is azido and R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl, in a compound of formula XIV
In starting substances of formula according to process variant a), reactive esterified hydroxy signifies, for example, hydroxy which is esterified with a hydrohalic acid or an organic sulfonic acid, such as halogen, especially chlorine, or optionally halogenated lower alkane sulfonyloxy, such as methane sulfonyloxy or trifluoromethane sulfonyloxy.
The reaction of compounds of formulae IV and V is effected in the usual manner, preferably in the presence of an acidic condensation agent, for example a Lewis acid, especially aluminium trichloride, advantageously in an inert solvent, such as a halogenated hydrocarbon, such as methylene chloride, if necessary whilst cooling, preferably in a temperature range from ca. 5°C to ca. 30°C, for example at room temperature.
The solvolysis of compounds of formula VI according to process variant b) is effected by conventional solvolysis processes, preferably under the conditions of a basic hydrolysis, for example by treatment with sodium hydroxide in an aqueous lower alkanol, such as methanol/water mixtures, advantageously with heating, preferably in a temperature range from ca. 55°C to ca. 90°C, for example at boiling temperature.
The conversion of the hydroxy group R4 into hydroxy C1-C7- alkoxy according to process variant c) may take place in conventional manner, for example by a reaction with a reactive monoester, such as a hydrohalic acid ester or sulfonic acid ester of a C1-C7- alkanediol, such as a ω-hydroxy C1-C7- alkyl halide, if necessary in the presence of a basic condensation agent, such as an alkali metal or alkaline earth metal hydroxide or an alkali metal carbonate, advantageously in a solvent which is inert towards the reaction components, if necessary with heating, for example in a temperature range of ca. 60°C to ca. 100°C, preferably by reacting with a ω-hydroxy C1-C7- alkyl halide in the presence of potassium carbonate in boiling acetonitrile.
Conversion of the hydroxy C1-C7- alkoxy group R'4 into C1-C7- alkoxy C1-C7- alkoxy R"4 according to process variant d) may take place in conventional manner, for example by a reaction with a reactive ester of a C1-C7- alkanol, such as corresponding halides, sulfates or optionally halogenated C1-C7- alkane sulfonates, such as methane sulfonates or trifluoromethane sulfonates, if necessary in the presence of a basic condensation agent, such as an alkali metal or alkaline earth metal hydroxide, advantageously in a solvent which is inert towards the reaction components, if necessary with heating, for example in a temperature range of ca. 30°C to ca. 60°C, preferably by reacting with a di-lower alkyl sulfate in the presence of potassium hydroxide in toluene at ca. 40°C.
Suitable amines for the reaction of compounds of formula IX according to process variant e) are chiral primary amines which are customary for the purpose of stereoselective synthesis, such as (S)-1-phenylethylamine or (S)-2-amino-1-methoxy-3-phenylpropane. The reaction of compounds of formula IX firstly with a chiral primary amine and then with a 1,4-dihalobut-2-ene is preferably carried out in a one-pot reaction without isolation of the intermediates in a solvent which is suitable for both steps, such as a solvent forming an azeotropic mixture with water, e.g. benzene or preferably toluene, if necessary adding one further or several further solvent(s), and in the second step adding a basic condensation agent, such as an alkali metal amide derivative, such as a N,N-bis(tri- C1-C7--alkylsilyl)-alkali metal amide, as well as a tertiary amide or lactam. Preferably, a solution of the compound of formula IX and the chiral amine is heated in toluene, firstly whilst distilling the reaction water, e.g. in a water separator, then concentrating to ca. two thirds to one half, then the basic condensation agent is added, for example a solution of a N,N-bis(tri- C1-C7--alkylsilyl)-alkali metal amide, preferably N,N-bis(trimethylsilyl)-lithium amide, in an ether-like solvent, such as tetrahydrofuran, and if necessary a tertiary amide or lactam is added, e.g. dimethylpropylene urea, then a solution of 1,4-dihalobut-2-ene is added whilst cooling, for example in a temperature range of ca. -10°C to ca. +10°C, and heated to room temperature, and working up is effected under slightly acidic conditions.
In the reaction with compounds of formula X or 1,4-dihalobut-2-enes according to process variant f), suitable compounds of formula XI are, for example, those in which X2 signifies a chiral amino, amido, urethane or alcohol group. Compounds containing groups of this kind are, for example, chiral amines, amides, urethanes and alcohols, which are customary for the purpose of stereoselective synthesis, for example pseudoephedrine, 4(S)-benzyl-2-oxo-oxazolidine, camphor sultam, borneol, intermediately-protected (S,S)- or (R,R)-2-aminophenylpropanediol, menthol, 8-phenylmenthol, pantolactone and the like.
The reaction of compounds of formulae X and XI, likewise the reaction of 1,4-dihalo-but-2-enes and compounds of formula XI, preferably takes place in the presence of a basic condensation agent, for example an alkali metal amide derivative, such as a N,N-bis-(tri- C1-C7-alkylsilyl)-alkali metal amide, e.g. N,N-bis-(trimethylsilyl)-lithium amide, as well as a tertiary amide or lactam, advantageously in a solvent which is inert towards the reaction components, such as toluene, if necessary whilst cooling, e.g. in a temperature range from ca. -10°C to ca. +10°C, in an ether-like solvent, such as tetrahydrofuran, adding a solution of the 1,4-dihalo-but-2-ene whilst cooling, for example in a temperature range from ca. -10°C to ca. +10°C and working up under slightly acidic conditions, and heating to room temperature and working up under slightly acidic conditions.
Suitable amines for the reaction of compounds of formula IX are, for example, chiral primary amines which are customary for the purpose of stereoselective synthesis, such as (S)-1-phenylethylamine or (S)-2-amino-1-methoxy-3-phenylpropane.
The reaction of compounds of formula IX firstly with a chiral primary amine and then with an intermediate formed by reacting a 1,4-dihalobut-2-ene with a compound of formula XI, is preferably carried out in a one-pot reaction without isolation of the intermediates in a solvent which is suitable for both steps, such as a solvent forming an azeotropic mixture with water, e.g. benzene or preferably toluene, if necessary adding one further or several further solvent(s), and in the second step adding a basic condensation agent, such as an alkali metal amide derivative, such as a N,N-bis(tri- C1-C7-alkylsilyl)-alkali metal amide, as well as a tertiary amide or lactam. Preferably, a solution of the compound of formula IX and the chiral amine of formula XII is heated in toluene, firstly whilst distilling the reaction water, e.g. in a water separator, then concentrating to ca. two thirds to one half, then the basic condensation agent is added, for example a solution of a N,N-bis(tri- C1-C7-alkylsilyl)-alkali metal amide, preferably N,N-bis(trimethylsilyl)-lithium amide, in an ether-like solvent, such as tetrahydrofuran, and if necessary a tertiary amide or lactam is added, e.g. dimethylpropylene urea, then a solution of the intermediate formed by reacting a 1,4-dihalobut-2-ene with a compound of formula XI is added whilst cooling, for example in a temperature range of ca. -10° to ca. +10°C, heated to room temperature, and working up is effected under slightly acidic conditions.
The intramolecular condensation of compounds of formula XIII with lactonisation is carried out, for example, by treatment with a halogenation agent, such as a N-halo-dicarboxylic acid imide, for example N-bromosuccinimide, advantageously in a two-phase solvent system, such as dichloromethane/water. The stereoselective exchange of halogen R5 into another reactive etherified hydroxy groupas defined in claim 1 R5 may be carried out in a conventional manner.
The stereoselective replacement of halogen R5 with azido according to process variant g) is effected in the usual manner, for example by a reaction with a metal or ammonium azide, for example with sodium azide, preferably in the presence of a quaternary nitrogen base, such as a quaternary aliphatic amine, e.g. N,N,N-tricapryl-N-methyl-ammonium chloride, if necessary whilst heating, e.g. in a temperature range from ca. 50°C to ca. 100°C, advantageously in a two-phase solvent system, such as toluene/water.
According to the intended use of compounds of formula I prepared according to the invention, a further object of the invention is a process for the production of compounds of formula II - h) a compound of formula I, wherein R is a group of formula Id, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy, R6 is azido and R7 is C1-C7-alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl, the azido group R6 is reduced to amino, and at the same time or subsequently, the benzoyl group is reduced to the corresponding benzyl group, for example by catalytic hydrogenation, for example in the presence of a palladium catalyst, such as palladium on carbon, at normal pressure and at room temperature, advantageously in a C1-C7- alkanol, such as ethanol, especially in a mixture with an aliphatic amino-alkanol, such as ethanolamine.
- Salts of compounds of formula I and II, which are obtainable by the process, can be converted in known manner into the free compounds. For example, salts of compounds of formula II can be converted by treatment with a base, such as an alkali metal hydroxide, a metal carbonate or hydrogen carbonate, or ammonia, or with another salt-forming base mentioned initially, or with an acid, such as a mineral acid, e.g. hydrochloric acid, or with another salt-forming acid mentioned initially.
- The following examples serve to illustrate the invention; the temperatures are indicated in degrees Celsius, and pressures in mbar.
- 7.2 g of isovaleroyl chloride are dissolved in 30 ml of methylene chloride and mixed with 10.6 g of water-free aluminium chloride. Then, a total of 5.5 g of guaiacol carbonate is added in portions, whereby the reaction temperature is maintained at 20°, if necessary by cooling. The mixture is stirred for 1 hour at room temperature, poured onto ice, extracted with ethyl acetate, the organic phase separated, dried over sodium sulfate, concentrated by evaporation and crystallised from toluene. 86% of theory of the title compound is obtained, with a m.p. of 120-122°.
- A solution of 7.0 g of bis-(3-isovaleroyl-6-methoxyphenyl)carbonate in 20 ml of methanol is mixed with 7 ml of 30% sodium hydroxide solution and heated at reflux whilst stirring for 1½ hours. The mixture is cooled to room temperature, mixed with 50 ml of water, slightly acidified with acetic acid, extracted with toluene and evaporated to dryness. The residue, which is oily at first, crystallises upon standing. 97% of theory of the title compound is obtained, with a m.p. of 51-53°.
- 55 g of potassium carbonate and 30 ml of 3-chloro-1-propanol are added to a solution of 55 g of 1-(3-hydroxy-4-methoxy-phenyl)-3-methyl-butan-1-one in 250 ml of acetonitrile, and stirred at reflux for 20 hours. The suspension is filtered and concentrated by evaporation. 81 g of the title compound are obtained as the residue of evaporation. It crystallises upon cooling, m.p. 38-40°C.
- 40 g of powdered potassium hydroxide and 30 ml of dimethyl sulfate are added at 22-26°C to a solution of 50 g of 1-(3-(3-hydroxypropyloxy)-4-methoxy-phenyl]-3-methyl-butan-1-one in 150 ml of toluene. The mixture is stirred for 8 hours at 40°C. Then, 150 ml of water are added, and stirring continues for a further 12 hours at room temperature. The organic solvent is separated and concentrated, and the residue distilled under a high vacuum (220°C, 0.05 torr) 41 g is obtained as an oil. The total yield of examples 3 and 4 is 90% of theory.
- A solution of 15.8 g of 1-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-3-methyl-butan-1-one and 9.3 g of (S)-(-)-2-amino-1-methoxy-3-phenylpropane in 100 ml of toluene is boiled whilst removing water until ca. 1 ml of water has been removed. Ca. 60 ml of toluene is distilled off. To the remaining solution of the imine of 1-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-3-methyl-butan-1-one are added at 0°C first of all 63 ml of a 1-molar solution of bis-trimethylsilyl-lithium amide in dry tetrahydrofuran and then 15.2 g of dimethylpropylene urea. The solution obtained is added dropwise at 0°C to a solution of 16 g of trans 1,4-dibromobut-2-ene in 26 ml of toluene. After stirring, the mixture is acidified with diluted hydrochloric acid, separated, and the organic solution concentrated. The crude product is purified by chromatography on a column of silica gel (eluant: hexanelethyl acetate 85:15).
- To a solution of 5.6 g of N-isovaleroyl-(S)-4-benzyl-oxazolidin-2-one in 12 ml of toluene are added, at 0°C, first of all 23.5 ml of a 1-molar solution of bis-trimethylsilyl-lithium amide in tetrahydrofuran, then 5.7 g of dimethylpropylene urea. The solution obtained is added dropwise at 0°C to a solution of 6 g of trans -1,4-dibromobut-2-ene in 10 ml of toluene. After stirring, the mixture is acidified with diluted hydrochloric acid, separated, and the organic solution concentrated. The crude product is purified by chromatography on a column of silica gel (eluant: hexane/ethyl acetate 85:15).
- A solution of 5.6 g of 1-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-3-methyl-butan-1-one and 3.3 g of (S)-(-)-2-amino-1-methoxy-3-phenylpropane in 30 ml of toluene is boiled whilst removing water until ca. 0.3 ml of water has been removed. Ca. 20 ml of toluene is distilled off. To the remaining solution of the imine of 1-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-3-methyl-butan-1-one are added at 0 °C first of all 23.5 ml of a 1-molar solution of bis-trimethylsilyl-lithium amide in tetrahydrofuran and then 5.7 g of dimethylpropylene urea. The solution obtained is added dropwise at 0°C to a solution of 8 g of trans-1-bromo-6-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl]-5-(S)-isopropyl-hex-2-en-6-one in 10 ml of tolulene. After stirring, the mixture is acidified with diluted hydrochloric acid, separated, and the organic solution concentrated. The crude product is purified by chromatography on a column of silica gel (eluant: hexane/ethyl acetate 85:15).
- To a solution of 5.6 g of N-isovaleroyl-(S)-4-benzyl-oxazolidin-2-one in 12 ml of toluene are added, at 0°C, first of all 23.5 ml of a 1-molar solution of bis-trimethylsilyl-lithium amide in tetrahydrofuran, then 5.7 g of dimethylpropylene urea. The solution obtained is added dropwise at 0°C to a solution of 8 g of trans-1-bromo-6-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-5-(S)-isopropyl-hex-2-en-6-one in 10 ml of tolulene. After stirring, the mixture is acidified with diluted hydrochloric acid, separated, and the organic solution concentrated. The crude product is purified by chromatography on a column of silica gel (eluant: hexane/ethyl acetate 85:15).
- 3.6 g of N-bromosuccinimide are added at room temperature to a solution of 11 g of trans-1-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl]-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-2(S)-7(S)-diisopropyl-oct-4-en-1,8-dione in 50 ml of methylene chloride and 50 ml of water. The mixture is stirred for 2 hours, then the organic phase is separated and concentrated. The crude product is purified by chromatography on a column of silica gel (eluant: hexane/ethyl acetate 85:15).
- A well stirred mixture of 25 g of 3(S)-isopropyl-5(S)-{1(R)-bromo-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-4-oxo-butyl}-tetrahydrofuran-2-one, 12.5g of sodium azide, 260 ml of toluene, 1.1 g of N-methyl-N,N,N-tricapryl-ammonium chloride and 38 ml of water is held at 75°C for 40 hours. Then, the mixture is cooled to 20°C, the organic solution separated, washed with an aqueous solution of sodium nitrate and acetic acid, and concentrated.
- A solution of 11 g of 3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-4-oxo-butyl}-tetrahydrofuran-2-one and 1.2 ml ethanolamin in 670 ml of ethanol is hydrogenated for 24 hours at room temperature and at normal pressure in the presence of 11 g of palladium on activated carbon (10%). After filtering the catalyst, the mixture is concentrated and the residue partitioned between aqueous sodium hydrogen carbonate solution and toluene. After concentrating the toluene, the product is obtained as a colourless resin.
Claims (6)
- Compounds of formula I
R is a group of formulae Ia, Ib, Ic or Id
R2 is C1-C7- alkyl or cycloalkyl,
R3 is C1-C7- alkoxy,
R4 is C1-C7- alkoxy C1-C7- alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy C1-C7- alkoxy or a group of formula Ie
R6 is azido and
R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl,
and their salts, wherein reactive esterified hydroxyl is selected from the group consisting of halogen or C1-C7- alkanesulfonyloxy, halogen C1-C7- alkanesulfonyl,; or benzenesulfonyloxy or naphthalenesulfonyloxy either unsubstituted or substituted by C1-C7-alkyl, halogen and/or nitro. - Compounds according to claim 1, wherein
R is a group of formulae la, Ib, Ic or Id,
R1 is 4-halogenbut-2-enyl ,
R2 is C1-C7- alkyl or 3- to 8-membered cycloalkyl,
R3 is C1-C7- alkoxy,
R4 is C1-C7- alkoxy C1-C7- alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy C1-C7- alkoxy or a group of formula Ie,
R5 is halogen or C1-C7- alkane sulfonyloxy, halogen C1-C7- alkane sulfonyl; or benzene sulfonyloxy or naphthalene sulfonyloxy which is unsubstituted or substituted by C1-C7- alkyl, halogen and/or nitro.
R6 is azido and
R7 is C1-C7- alkyl, C1-C7- alkenyl, 3- to 8-membered cycloalkyl, or phenyl C1-C7- alkyl which is unsubstituted or substituted in the phenyl moiety by C1-C7- alkyl, C1-C7- alkoxy, halogen and/or nitro,
and their salts. - Compounds according to claim 1, wherein
R is a group of formulae Ia, Ib, Ic or Id,
R1 is 4-halogenbut-2-enyl ,
R2 is branched C3-C7-alkyl, such as propyl,
R3 is C1-C4-alkoxy, such as methoxy,
R4 is C1-C4-alkoxy-C2-C4-alkoxy, such as 3-methoxypropyloxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy-C2-C4-alkoxy, such as 3-hydroxypropyloxy, or a group of formula Ie,
R5 is halogen of atomic numbers up to and including 35, such as bromine,
R6 is azido or amino and
R7 is branched C3-C7-alkyl, such as propyl,
and their salts. - A compound according to claim 1, selected from
Bis-(3-isovaleroyl-6-methoxy-phenyl)-carbonate;
1-(3-hydroxy-4-methoxy-phenyl)-3-methyl-butan-1-one;
1-[3-(3-hydroxypropyloxy)-4-methoxy-phenyl]-3-methyl-butan-1-one
1-[4-methoxy 3-(3-methoxypropyloxy)-phenyl]-3-methyl-butan-1-one;
trans-1-bromo-6-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-5-(S)-isopropyl-hex-2-en-6-one;
3(S)-isopropyl-5(S)-{1(R)-bromo-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropoxy)phenyl]-4-oxo-butyl}-tetrahydrofuran-2-one and
3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)phenyl]-4-oxo-butyl}-tetrahydrofuran-2-one. - Method of producing compounds of formula I
R is a group of formulae la, Ib, Ic or Id
R2 is C1-C7- alkyl or cycloalkyl,
R3 is C1-C7- alkoxy,
R4 is C1-C7- alkoxy C1-C7- alkoxy, or where R is a group of formula (Ia), it is hydroxy, hydroxy C1-C7- alkoxy or a group of formula Ie
R6 is azido and
R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl,
and their salts, characterised in thata) in order to produce compounds of formula I, wherein R is a group of formula Ia, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is a group of formula Ie,
a compound of formula IVb) in order to produce a compound of formula I, wherein R is a group of formula la, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is hydroxy, a compound of formula VI,c) in order to produce a compound of formula I, wherein R is a group of formula Ia, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is hydroxy C1-C7- alkoxy R'4, in a compound
of formula VII,d) in order to produce a compound of formula I, wherein R is a group of formula la, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is C1-C7- alkoxy C1-C7- alkoxy R"4, in a
compound of formula VIII,e) in order to produce compounds of formula I, wherein R is a group of formula Ib, R1 is 4-halogen-but-2-enyl, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy and R4 is C1-C7-alkoxy C1-C7- alkoxy R"4, a compound of formula IXf) in order to produce compounds of formula I, wherein R is a group of formula Ic, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy R"4, R5 is reactive esterified hydroxy and R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7-alkyl,
a compound of formula X,g) in order to produce compounds of formula I, wherein R is a group of formula Id, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy R"4, R6 is azido and R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl, in a compound of formula XIV - Method of producing compounds of formula II
R2 is C1-C7- alkyl or cycloalkyl,
R3 is C1-C7- alkoxy,
R4 is C1-C7- alkoxy C1-C7- alkoxy and
R7 is C1-C7- alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl,
characterised in thata) a compound of formula IV,b) in the obtained compound of formula VIc) in the obtained compounds of formula VIId) in the obtained compounds of formula VIIIe) the obtained compound of formula IXf) the obtained compound of formula Xg) in the obtained compounds of formula XIVh) in a compound of formula I, wherein R is a group of formula Id, R2 is C1-C7- alkyl or cycloalkyl, R3 is C1-C7- alkoxy, R4 is C1-C7- alkoxy C1-C7- alkoxy, R6 is azido and R7 is C1-C7-alkyl, C1-C7- alkenyl, cycloalkyl or aryl C1-C7- alkyl, the azido group R6 is reduced to amino, and at the same time or subsequently, the benzoyl group is reduced to the corresponding benzyl group, and if desired, a free compound obtainable according to the method is converted into a salt, or a salt obtainable according to the method is converted into the free compound or into another salt.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06762514T PL1904469T3 (en) | 2005-07-11 | 2006-07-10 | New pyrocatechin derivatives |
EP06762514A EP1904469B1 (en) | 2005-07-11 | 2006-07-10 | New pyrocatechin derivatives |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05014950 | 2005-07-11 | ||
PCT/EP2006/006731 WO2007006532A1 (en) | 2005-07-11 | 2006-07-10 | New pyrocatechin derivatives |
EP06762514A EP1904469B1 (en) | 2005-07-11 | 2006-07-10 | New pyrocatechin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1904469A1 EP1904469A1 (en) | 2008-04-02 |
EP1904469B1 true EP1904469B1 (en) | 2011-09-21 |
Family
ID=36940633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06762514A Not-in-force EP1904469B1 (en) | 2005-07-11 | 2006-07-10 | New pyrocatechin derivatives |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090143340A1 (en) |
EP (1) | EP1904469B1 (en) |
JP (1) | JP5123178B2 (en) |
KR (1) | KR20080023730A (en) |
CN (1) | CN101218218B (en) |
AT (1) | ATE525367T1 (en) |
AU (1) | AU2006268907B2 (en) |
BR (1) | BRPI0612819A2 (en) |
CA (1) | CA2614715A1 (en) |
ES (1) | ES2374096T3 (en) |
MX (1) | MX2008000469A (en) |
PL (1) | PL1904469T3 (en) |
PT (1) | PT1904469E (en) |
RU (1) | RU2470018C2 (en) |
WO (1) | WO2007006532A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005052195A1 (en) * | 2005-10-28 | 2007-05-03 | Reuter Chemischer Apparatebau Kg | Process for the preparation of chiral octenoic acid derivatives |
DE102006017681A1 (en) * | 2006-04-12 | 2007-10-18 | Reuter Chemischer Apparatebau Kg | Process for the preparation of 8-aryl-octanoyl derivatives |
SI2189442T1 (en) * | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process and intermediates for the preparation of aliskiren |
WO2011051853A1 (en) * | 2009-10-29 | 2011-05-05 | CarboDesign LLC | Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren |
CN102485722B (en) * | 2010-12-06 | 2014-05-07 | 博瑞生物医药技术(苏州)有限公司 | Aliskiren, its intermediates and medicinal salt, as well as preparation method thereof |
US8703976B2 (en) | 2011-10-02 | 2014-04-22 | Milan Soukup | Manufacturing process for 8-aryloctanoic acids such as Aliskiren |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
AU7376301A (en) | 2000-07-05 | 2002-01-14 | Speedel Pharma Ag | Process for the preparation of substituted octanoyl amides |
TR200401871T4 (en) * | 2000-07-25 | 2004-08-23 | Speedel Pharma Ag | Preparation of modified octanoyl amides (octanoyl amides) |
RU2235713C1 (en) * | 2003-01-14 | 2004-09-10 | Закрытое акционерное общество "Щелково Агрохим" | Method for preparing phenylacetone |
-
2006
- 2006-07-10 RU RU2008104511/04A patent/RU2470018C2/en not_active IP Right Cessation
- 2006-07-10 ES ES06762514T patent/ES2374096T3/en active Active
- 2006-07-10 CN CN2006800247968A patent/CN101218218B/en not_active Expired - Fee Related
- 2006-07-10 KR KR1020087000724A patent/KR20080023730A/en not_active Application Discontinuation
- 2006-07-10 EP EP06762514A patent/EP1904469B1/en not_active Not-in-force
- 2006-07-10 PL PL06762514T patent/PL1904469T3/en unknown
- 2006-07-10 PT PT06762514T patent/PT1904469E/en unknown
- 2006-07-10 WO PCT/EP2006/006731 patent/WO2007006532A1/en active Application Filing
- 2006-07-10 CA CA002614715A patent/CA2614715A1/en not_active Abandoned
- 2006-07-10 JP JP2008520771A patent/JP5123178B2/en not_active Expired - Fee Related
- 2006-07-10 AU AU2006268907A patent/AU2006268907B2/en not_active Ceased
- 2006-07-10 US US11/994,919 patent/US20090143340A1/en not_active Abandoned
- 2006-07-10 BR BRPI0612819-0A patent/BRPI0612819A2/en not_active IP Right Cessation
- 2006-07-10 MX MX2008000469A patent/MX2008000469A/en active IP Right Grant
- 2006-07-10 AT AT06762514T patent/ATE525367T1/en active
Also Published As
Publication number | Publication date |
---|---|
AU2006268907A1 (en) | 2007-01-18 |
KR20080023730A (en) | 2008-03-14 |
BRPI0612819A2 (en) | 2010-11-30 |
PL1904469T3 (en) | 2012-02-29 |
CA2614715A1 (en) | 2007-01-18 |
JP2009500435A (en) | 2009-01-08 |
RU2008104511A (en) | 2009-08-20 |
CN101218218B (en) | 2012-10-10 |
CN101218218A (en) | 2008-07-09 |
RU2470018C2 (en) | 2012-12-20 |
US20090143340A1 (en) | 2009-06-04 |
JP5123178B2 (en) | 2013-01-16 |
MX2008000469A (en) | 2008-03-11 |
ES2374096T3 (en) | 2012-02-13 |
PT1904469E (en) | 2012-01-06 |
WO2007006532A1 (en) | 2007-01-18 |
EP1904469A1 (en) | 2008-04-02 |
ATE525367T1 (en) | 2011-10-15 |
AU2006268907B2 (en) | 2010-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0136863B1 (en) | Processes for preparing picenadol precursors and novel intermediates therefor | |
US5225585A (en) | Production of fluoxetine and new intermediates | |
EP1904469B1 (en) | New pyrocatechin derivatives | |
US4403096A (en) | Optically active imidazolidin-2-one derivatives | |
US4172204A (en) | Method for preparing 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles and intermediates thereof | |
KR960000758B1 (en) | Optically active hydroxybenzylamine derivative, optically active | |
US4851588A (en) | Novel process for the preparation of bronopol | |
US5110957A (en) | Process for preparing 1,3-dioxolane ketones | |
US4231962A (en) | 3-Phenoxybenzylideneamines and 3-benzylbenzylideneamines | |
FI88292B (en) | FRAME STARTING FOR N- (SULPHONYLMETHYL) FORMAMIDER | |
US20040077098A1 (en) | Optical resolver and method of optically resolving alcohol with the same | |
GB2204584A (en) | Cyclobutenediones useful as intermediates | |
US6121492A (en) | Method for preparing 2-trifluoro-methoxy-aniline | |
US4533745A (en) | Amino ketones and their preparation | |
US4533754A (en) | Preparation of aldehydes from aryl acid halides and organozinc compounds with complex palladium catalysts | |
US4224224A (en) | Certain 1-(carbocyclic aryl)-1-halo(or mesyloxy or tosyloxy)-2-(3'-alkoxycarbonylguanidino) ethanes | |
JP3770678B2 (en) | Optically active alcohol and its carboxylic acid ester | |
WO2007000628A1 (en) | Intermediate of amorolfine or its salt | |
CN1070647A (en) | Preparation has the method for optically active false bufotoxin amidoalcohol | |
JPH0597735A (en) | Production of optically active secondary alcohol | |
JPH0977723A (en) | Production of optically active 1,2-diphenylethylenediamines | |
HUT61528A (en) | Process for producing aromatic amines suitable for the production of tetrahydroisoqinolino/2,1-c//1,3/benzodiazepines | |
EP1140832A1 (en) | Process for preparing arylpiperidine carbinol intermediates and derivatives | |
JPH0316338B2 (en) | ||
EP0075868A2 (en) | Optically active amino alcohols and their production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080211 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20090812 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602006024571 Country of ref document: DE Effective date: 20111208 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20111220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2374096 Country of ref document: ES Kind code of ref document: T3 Effective date: 20120213 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20110921 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20110403137 Country of ref document: GR Effective date: 20120206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120121 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110921 |
|
26N | No opposition filed |
Effective date: 20120622 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20120606 Year of fee payment: 7 Ref country code: GR Payment date: 20120619 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006024571 Country of ref document: DE Effective date: 20120622 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20120704 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20120713 Year of fee payment: 7 Ref country code: ES Payment date: 20120824 Year of fee payment: 7 Ref country code: FR Payment date: 20120719 Year of fee payment: 7 Ref country code: DE Payment date: 20120704 Year of fee payment: 7 Ref country code: IT Payment date: 20120713 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20120710 Year of fee payment: 7 Ref country code: PT Payment date: 20111220 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20120626 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120710 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20140110 |
|
BERE | Be: lapsed |
Owner name: NOVARTIS A.G. Effective date: 20130731 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20140201 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 525367 Country of ref document: AT Kind code of ref document: T Effective date: 20130710 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130710 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20110403137 Country of ref document: GR Effective date: 20140204 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602006024571 Country of ref document: DE Effective date: 20140201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20140331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130731 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140201 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130731 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140201 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130710 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140204 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120710 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130710 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130731 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130710 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20120621 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060710 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20140908 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: LAPE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130711 Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130710 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130710 |